STOCK TITAN

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.

Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.

The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.

Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.

Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.

This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.

Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 5th Annual Antifibrotic Drug Development Summit on November 3, 2021. Her presentation will highlight innovative strategies for promoting tissue regeneration, focusing on clinical trial data for Namodenoson, which showed a dose-dependent reduction in liver fat and fibrosis in a Phase IIa study. The Phase IIb study is currently approved and underway, while Can-Fite continues to advance its clinical pipeline in cancer and liver diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences clinical trial
-
Rhea-AI Summary

Can-Fite BioPharma Ltd (NYSE: CANF) announced the publication of a study on Namodenoson for treating non-alcoholic fatty liver disease (NASH) in the journal Alimentary Pharmacology & Therapeutics. The Phase IIa trial met its endpoints, showcasing significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects. A Phase IIb trial is set to enroll patients in Q4 2021. The market for NASH treatments is projected to reach $35-40 billion by 2025. With no current U.S. approved drugs for NASH, the potential for Namodenoson is substantial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the NASH Investor Conference on October 12, 2021, at 9:30 am ET. The conference will include a panel of experts discussing NASH, a liver disease with no approved treatments in the U.S. Can-Fite's drug candidate, Namodenoson, is set to enter a Phase IIb trial for NASH in Q4 2021, following successful Phase IIa results. The NASH market is projected to reach $35-40 billion by 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
conferences
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) will have CEO Dr. Pnina Fishman present at the Benzinga Healthcare Small Cap Conference on September 29, 2021.

The presentation will include a panel discussion on medical cannabis and insights into Can-Fite’s drug development efforts, including ongoing trials for Piclidenoson and Namodenoson targeting psoriasis and liver cancer. With FDA designations for Namodenoson, Can-Fite aims to capture significant market opportunities in the pharmaceutical industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma Ltd (NYSE American: CANF) has secured approximately $20 million from partnering deals, with potential for an additional $130 million in milestone payments and royalties. The company will participate in three upcoming virtual conferences to meet with potential partners for its drug candidates targeting cancer, liver diseases, and inflammation. Key events include BioPharm America 2021 (Sept 20-23), TAP Diabetes 2021 (Oct 5-7), and BIO-Europe 2021 (Oct 25-29). Can-Fite's leading candidates are in advanced clinical stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the company's proprietary small molecule drugs aimed at inflammatory, cancer, and liver diseases, with a special emphasis on Piclidenoson and Namodenoson, which are advancing through various clinical trials. The presentation will be available on the conference portal at 7:00 AM ET on September 13.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
Rhea-AI Summary

Can-Fite BioPharma has completed enrollment of over 400 patients for its Phase III Comfort™ study targeting moderate to severe plaque psoriasis. The study follows a positive interim analysis from October 2020, which recommended continuation based on data from 200 patients. Topline results are anticipated in Q1 2022. This randomized, double-blind study is being conducted in Europe, Israel, and Canada, with primary endpoints focused on patient response rates. Can-Fite’s lead candidate, Piclidenoson, aims to offer an effective oral treatment alternative in a growing $11.3 billion market by 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced its financial results for Q2 2021. The company reported immaterial revenue decline to $0.39 million compared to $0.40 million in Q2 2020. Notable developments include a $3 billion commercialization agreement for Piclidenoson in veterinary osteoarthritis and a Notice Allowance for a NASH patent in China. The net loss decreased to $5.09 million from $8.23 million year over year. Can-Fite has approximately $7.5 million in cash while anticipating significant milestones in upcoming studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE: CANF) has signed a definitive agreement with a healthcare-focused institutional investor to sell 5,000,000 American Depositary Shares (ADSs) at $2.00 each, raising gross proceeds of $10 million for research, development, and working capital. A concurrent private placement of warrants to purchase up to 5,000,000 ADSs will also occur at the same price. The offering, expected to close around August 16, 2021, is facilitated by H.C. Wainwright & Co. The ADSs are offered under a shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) has appointed Yossi Borenstein as an External Director during its recent annual general meeting. Borenstein, CEO of Shizim Group and a veteran in the Israeli biomed industry, brings over 35 years of experience, having previously managed Bristol-Myers Squibb (Israel) and served in various leadership roles across multiple organizations. Can-Fite, engaged in developing therapies for cancer, liver, and inflammatory diseases, continues its clinical progress with drug candidates like Piclidenoson and Namodenoson.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none

FAQ

What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is $1.625 as of December 31, 2024.

What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?

The market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF) is approximately 9.6M.

What does Can-Fite BioPharma Ltd. specialize in?

Can-Fite BioPharma specializes in developing orally bioavailable small molecule therapeutic products for cancer, liver, and inflammatory diseases.

Where is Can-Fite BioPharma Ltd. located?

Can-Fite BioPharma Ltd. is headquartered at 10 Bareket Street, פ"ת, Israel.

What is Piclidenoson?

Piclidenoson is a drug candidate from Can-Fite BioPharma currently in Phase III clinical trials for treating psoriasis.

What is Namodenoson used for?

Namodenoson is aimed at treating liver conditions such as hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis (NASH).

What stage are the trials for Namodenoson?

Namodenoson is in a Phase III trial for HCC and a Phase IIb trial for NASH.

What is the A3 adenosine receptor (A3AR)?

The A3 adenosine receptor (A3AR) is a therapeutic target used by Can-Fite BioPharma's platform technology for drug development.

How does Can-Fite BioPharma's technology benefit patients?

Can-Fite BioPharma's technology focuses on developing oral therapeutics, which are easier to administer, potentially improving patient compliance and treatment outcomes.

What is the significance of Can-Fite BioPharma's partnerships?

Partnerships with research institutions and other entities help Can-Fite BioPharma advance its drug development programs and bring innovative therapies to market.

Is Can-Fite BioPharma listed on any stock exchange?

Yes, Can-Fite BioPharma Ltd. is listed on NASDAQ under the symbol CANF.

What is the focus of Can-Fite BioPharma's current projects?

The current focus includes advanced clinical trials for drugs treating psoriasis, hepatocellular carcinoma (HCC), and non-alcoholic steatohepatitis (NASH).
Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares

NYSE:CANF

CANF Rankings

CANF Stock Data

9.57M
6.10M
8.02%
2.24%
Biotechnology
Healthcare
Link
United States of America
Ramat Gan